Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    -2.00 (-2.84%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

26 Jan 2006 08:23

Readybuy PLC26 January 2006 Readybuy Plc Interim Announcement for the six months ended 31 October 2005 Chairman's Statement The results for the six months to 31 October show a loss of £85,000. Thisreflects the costs of closure of the manufacturing facility and also atermination payment to the former Chief Executive. The group has now exited completely from chilled food manufacturing. The ongoing costs are now minimal as the board seeks to preserve as much cash aspossible. We continue to explore a number of opportunities and I hope to be ableto announce some progress in the near future. Colin Davies Chairman READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months to 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 Notes £'000 £'000 £'000 Turnover 4 313 139 ______ ______ ______ Operating loss (84) (252) (137) Provision for loss on operations to be discontinued - (804) - ______ ______ ______ Loss on ordinary activities before interest (84) (1,056) (137) Net interest (1) (2) (1) ______ ______ ______ Loss before taxation (85) (1,058) (138) Taxation - (45) - ______ ______ ______ Loss after taxation (85) (1,103) (138) Dividends - - - ______ ______ ______ Retained loss (85) (1,103) (138) ______ ______ ______ ---------- ----------- ---------- Loss per shareBasic and diluted 3 (0.4)p (6.1)p (0.8)p Dividends per share - - - The group's trading activities were terminated in July 2005, therefore all ofthe above activities are classified as discontinued. READYBUY PLCGROUP BALANCE SHEETat 31 October 2005 Unaudited Audited Unaudited 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Fixed assets Goodwill - - 629 Tangible assets - - 208 ______ ______ ______ - - 837 Current assetsStock - 2 17 Debtors 3 44 116Cash at bank 38 169 276 ______ ______ ______ 41 215 409 ______ ______ ______ Creditors falling due within one year (5) (194) (334) ______ ______ ______ Net current assets 36 21 75 ______ ______ ______ Total assets less current liabilities 36 21 912 Creditors falling due after one year - - (16) ______ ______ ______ 36 21 896 ______ ______ ______ ----------- ---------- ---------- Capital and reservesCalled up share capital 97 93 90Share premium account 1,425 1,329 1,242Profit and loss account (1,486) (1,401) (436) ______ ______ ______ Equity shareholders' funds 36 21 896 ______ ______ ______ ----------- ---------- ---------- READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Operating loss (84) (252) (137) Gain on sale of fixed assets (25) - - Depreciation and amortisation - 67 33 Movement in working capital (21) 105 (17) Net cash outflow from operating activities (130) (80) (121) Net cash outflow from servicing of finance (1) (2) - Net cash inflow/(outflow) from capital expenditure and 25 (8) (6) financial investment Net cash outflow before use of liquid resources and financing (106) (90) (127) Capital element of finance lease payments (25) (34) (25) Repayment of convertible loans (100) - - Issue of ordinary share capital net of redemption 100 90 - Net cash (outflow)/inflow from financing (25) 56 (25) Decrease in cash in the period (131) (34) (152) Analysis of net funds Cash at bank and in hand 38 169 276 Overdraft - - (225) 38 169 51 Debt repayable by instalments: Due within one year - (25) (18) Due after more than one year - - (16) 38 (25) (34) 38 144 17 READYBUY PLCINTERIM ACCOUNTSfor the six months to 31 October 2005 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2005 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. 2 The figures for the period ended 30 April 2005 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of earnings per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 19,240,387 (31 October 2004 - 17,994,010 and period ended 30 April 2005 - 18,066,870). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day
13th Feb 20237:00 amRNSIssue of Equity and Total Voting Rights
23rd Jan 202312:20 pmRNSIssue of Equity and Total Voting Rights
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSSuccessful Completion of Fourth Dose Escalation
16th Jan 202310:15 amRNSBlock Listing Application to AIM
19th Dec 20227:00 amRNSAvacta to Host Therapeutics Division Science Day
8th Nov 20227:01 amRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResult of the Open Offer
31st Oct 20221:32 pmRNSAvacta to Present at Theranostics FAP Summit
31st Oct 202211:05 amRNSSecond Price Monitoring Extn
31st Oct 202211:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSBlock Listing Six Monthly Return
20th Oct 20228:01 amRNSDirector/PDMR Shareholding
20th Oct 20228:01 amRNSAdmission of the Company’s Ordinary Shares
20th Oct 20227:00 amRNSPosting of the Company’s Open Offer Circular
18th Oct 202211:49 amRNSResult of Placing
18th Oct 20229:16 amRNSPrivate CB and ABB Launch
18th Oct 20229:14 amRNSProposed acquisition of Launch Diagnostics
29th Sep 20227:00 amRNSInterim Results for the Period Ended 30 June 2022
26th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSAVA6000 receives Orphan Drug Designation from FDA
1st Sep 20227:00 amRNSPhase I study of AVA6000 advances to fourth cohort
21st Jul 20227:00 amRNSAffyXell successfully completes funding round
30th Jun 20227:00 amRNSLG Chem renews license triggers payment to Avacta
29th Jun 20229:05 amRNSSecond Price Monitoring Extn
29th Jun 20229:00 amRNSPrice Monitoring Extension
29th Jun 20227:00 amRNSSecond dose escalation in phase 1 trial of AVA6000
23rd Jun 20224:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:36 pmRNSPrice Monitoring Extension
23rd Jun 20224:27 pmRNSResult of Annual General Meeting
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
31st May 20227:00 amRNSPosting of Annual Report and Notice of AGM
16th May 202212:00 pmRNSAffyXell expands partnership with GenScript ProBio
11th May 20227:00 amRNSLondon Therapeutics headquarters established
6th May 20227:00 amRNSBlock Listing Application to AIM (update)
28th Apr 20221:53 pmRNSBlock Listing Application to AIM
14th Apr 20225:01 pmRNSIssue of Equity and Total Voting Rights
14th Apr 202211:29 amRNSIssue of Equity and Total Voting Rights
13th Apr 20227:00 amRNSAffyXell milestone and increased equity stake
12th Apr 20227:00 amRNSPoster presented at the AACR available to download
11th Apr 20224:41 pmRNSSecond Price Monitoring Extn
11th Apr 20224:35 pmRNSPrice Monitoring Extension
11th Apr 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.